ArticleEuropean journal of medical research2025
Wuling San ameliorates cerebral ischemia-reperfusion injury via suppression of the TRPM2/NLRP3 pathway.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTRPM2, a potentially important target for the treatment of ischemic stroke, is closely related to inflammation, oxidative stress and neuronal death caused by cerebral ischemia-reperfusion. The NLRP3 inflammasome is an important mediator of post-ischemic inflammation, its inhibition can also regulate the distribution of AQP4 to reduce brain edema. In addition, inhibiting TRPM2/NLRP3 improves neuronal injury and oxidative stress mediated by oxygen-glucose deprivation. Therefore, inhibiting the TRPM2/NLRP3 pathway may be a potential therapeutic approach for ischemic stroke. Wuling San (WLS) has anti-inflammatory and antioxidant properties and can be used clinically to treat hydrocephalus and cerebral edema. However, its specific effects on and mechanism of action in cerebral ischemia-reperfusion injury (CIRI) remain unclear. This study aimed to explore whether Wuling San (WLS) can improve CIRI and whether its potential mechanism is related to the regulation of TRPM2.
methodsThe CIRI mouse model was constructed via bilateral carotid artery ligation and was intervened by gavage with different doses of WLS decoction. Behavioral, morphological, brain water content test and western blot (WB) analysis were used to determine the improvement effect of WLS on CIRI. The underlying mechanism of the protective effect of WLS was further explored. Therefore, a combined intervention of WLS and TRPM2 agonists was carried out in CIRI mice to determine whether the protective effect of WLS was reversed.
resultsWLS administration was found to alleviate neurological deficits and cognitive impairment and reduce brain damage in CIRI model mice. Moreover, WLS reduced AQP4 expression and improved cerebral edema. CIRI disrupted the polarized distribution of AQP4, resulting in AQP4 being mainly distributed in astrocytes bodies, whereas the distribution around the endfeet of astrocytes and blood vessels decreased. Interestingly, WLS intervention promoted the normalization of AQP4 polarization. Notably, WLS inhibits the downregulation of TJs, which is beneficial for protecting the BBB and may further alleviate brain edema. In addition, WLS treatment inhibited microglial overactivation and mitigated CIRI by inhibiting inflammation, oxidative stress and apoptosis. Furthermore, WLS downregulated the expression of TRPM2 and NLRP3. By combining WLS with a TRPM2 agonist in CIRI mice, we found that TRPM2 overexpression reversed the downregulatory effect of WLS on the NLRP3 level. It simultaneously reversed the protective effect of WLS.
conclusionsThe present study is the first to prove that WLS improved CIRI and regulated the polarization distribution of AQP4 by targeting the TRPM2/NLRP3 pathway to alleviate brain edema, which is beneficial for neuroprotection and cognitive improvement after CIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.